ASAS Consensus Definition of Early Axial Spondyloarthritis (2024)
https://pubmed.ncbi.nlm.nih.gov/37321799/

Patient-initiated follow-up supported by asynchronous telemedicine versus usual care in spondyloarthritis (TeleSpA-study): a randomised controlled trial of clinical and cost-effectiveness (2024)
https://pubmed.ncbi.nlm.nih.gov/39492125/

Barriers and facilitators to application of treat-to-target management in psoriatic arthritis and axial spondyloarthritis in practice: a systematic literature review (2024)
https://pubmed.ncbi.nlm.nih.gov/39277949/

Comparing the construct validity of measurement instruments for pain and stiffness in patients with axial spondyloarthritis: cross-sectional analysis in the OASIS cohort (2024)
https://pubmed.ncbi.nlm.nih.gov/39658054/

Effectiveness and cost-effectiveness of combined asynchronous telemonitoring and patient-initiated care for spondyloarthritis: protocol for a pragmatic multicentre randomised controlled trial (TeleSpA-study). (2023)
https://pubmed.ncbi.nlm.nih.gov/36806136/

Treating spondyloarthritis early: does it matter? Results from a systematic literature review. (2023)
https://pubmed.ncbi.nlm.nih.gov/36099043/

Go or no-go for treat-to-target in axial spondyloarthritis? (2023)
https://pubmed.ncbi.nlm.nih.gov/37071063/

Development of a web-based decision aid for initiating biologic or targeted synthetic disease modifying anti-rheumatic drugs (b/tsDMARDs) in axial spondyloarthritis. (2023)
https://pubmed.ncbi.nlm.nih.gov/37263741/

Treat-to-target in axial spondyloarthritis: an observational study in daily practice (2022)
https://pubmed.ncbi.nlm.nih.gov/34175950/

How is early spondyloarthritis defined in the literature? Results from a systematic review (2022)
https://pubmed.ncbi.nlm.nih.gov/35667332/

Are all routine spondyloarthritis outpatient visits considered useful by rheumatologists? An explorative clinical practice study. (2022)
https://pubmed.ncbi.nlm.nih.gov/35649557/

The impact of the COVID-19 pandemic on work productivity in patients with spondyloarthritis: results from the Dutch SpA-Net registry. (2022)
https://pubmed.ncbi.nlm.nih.gov/36109082/

Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial (2021)
https://pubmed.ncbi.nlm.nih.gov/33958325/

Progression from subclinical inflammation to overt SpA in first degree relatives of SpA patients is associated with HLA-B27: the Pre-SpA cohort (2021)
https://pubmed.ncbi.nlm.nih.gov/34219406/

Development and validation of an alternative ankylosing spondylitis disease activity score when patient global assessment is unavailable (2021)
https://pubmed.ncbi.nlm.nih.gov/32572483/

Infliximab treatment reduces depressive symptoms in patients with ankylosing spondylitis: an ancillary study to a randomized controlled trial (ASSERT) (2020)
https://pubmed.ncbi.nlm.nih.gov/32993799/

Validation and implementation of a patient-reported experience measure for patients with rheumatoid arthritis and spondyloarthritis in the Netherlands (2020)
https://pubmed.ncbi.nlm.nih.gov/32318970/

Validation of the self-administered comorbidity questionnaire adjusted for spondyloarthritis: results from the ASAS-COMOSPA study (2020)
https://pubmed.ncbi.nlm.nih.gov/31665462/

Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis (2020)
https://pubmed.ncbi.nlm.nih.gov/31604704/